Myovant Sciences Ltd. (MYOV) Research

Myovant Sciences Ltd. is a biopharmaceutical company focused on innovating healthcare solutions for both women and men. Its flagship product is relugolix, an orally administered, once-daily small molecule that functions as a gonadotropin-releasing hormone (GnRH) receptor antagonist. This medication is indicated for conditions such as heavy menstrual bleeding caused by uterine fibroids, pain associated with endometriosis, and advanced prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin agonist, currently in Phase II clinical trials for treating female infertility within assisted reproductive procedures. Myovant collaborates with Pfizer Inc. for the development and commercialization of relugolix across oncology and women's health sectors. Incorporated in 2016, initially as Roivant Endocrinology Ltd. before rebranding to Myovant Sciences Ltd. in May of that year, the firm is based in London, United Kingdom, and operates as a subsidiary of Sumitovant Biopharma Ltd.

Market snapshot

Symbol
MYOV
Price
$26.98
Day change
-0.04%
Market cap
$2.6B
P/E ratio
-12.18x
52-week range
7.67-27.06
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • BELLUS Health Inc. (BLU)
  • Calliditas Therapeutics AB (publ) (CALT)
  • DICE Therapeutics, Inc. (DICE)
  • Fusion Pharmaceuticals Inc. (FUSN)
  • Chinook Therapeutics, Inc. (KDNY)
  • Longboard Pharmaceuticals, Inc. (LBPH)
  • MorphoSys AG (MOR)
  • Morphic Holding, Inc. (MORF)

Recent insider activity

  • Valente Nancy — D-Return (3673 shares) on 2023-03-10
  • Valente Nancy — D-Return (36892 shares) on 2023-03-10
  • POTTER MYRTLE S — D-Return (45000 shares) on 2023-03-10
  • POTTER MYRTLE S — D-Return (58608 shares) on 2023-03-10
  • POTTER MYRTLE S — D-Return (21096 shares) on 2023-03-10

Open Myovant Sciences Ltd. (MYOV) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.